The benefits of using Bcl-3 blocking instead of recently approved CDK4/6 inhibitors are that targeting Bcl-3 will only affect metastatic melanoma cells, while CDK4/6 inhibitors affect all actively dividing cells. Here, CDK4 is linked to melanoma.